1262 related articles for article (PubMed ID: 38473776)
1. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract][Full Text] [Related]
2. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
Shah S
Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
[TBL] [Abstract][Full Text] [Related]
4. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
Lefranc F; Rynkowski M; DeWitte O; Kiss R
Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells.
Kardani K; Sanchez Gil J; Rabkin SD
Front Cell Infect Microbiol; 2023; 13():1206111. PubMed ID: 37325516
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi YR; Schulze AJ
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
[TBL] [Abstract][Full Text] [Related]
7. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of glioblastoma: Recent advances and future prospects.
Yuan B; Wang G; Tang X; Tong A; Zhou L
Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
[TBL] [Abstract][Full Text] [Related]
10. AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma.
Strecker MI; Wlotzka K; Strassheimer F; Roller B; Ludmirski G; König S; Röder J; Opitz C; Alekseeva T; Reul J; Sevenich L; Tonn T; Wels WS; Steinbach JP; Buchholz CJ; Burger MC
Oncoimmunology; 2022; 11(1):2127508. PubMed ID: 36249274
[TBL] [Abstract][Full Text] [Related]
11. Emerging therapies for glioblastoma: current state and future directions.
Rong L; Li N; Zhang Z
J Exp Clin Cancer Res; 2022 Apr; 41(1):142. PubMed ID: 35428347
[TBL] [Abstract][Full Text] [Related]
12. Insights in the immunobiology of glioblastoma.
Strepkos D; Markouli M; Klonou A; Piperi C; Papavassiliou AG
J Mol Med (Berl); 2020 Jan; 98(1):1-10. PubMed ID: 31650201
[TBL] [Abstract][Full Text] [Related]
13. An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment.
Verdugo E; Puerto I; Medina MÁ
Cancer Commun (Lond); 2022 Nov; 42(11):1083-1111. PubMed ID: 36129048
[TBL] [Abstract][Full Text] [Related]
14. Local immunotherapy of glioblastoma: A comprehensive review of the concept.
Sabahi M; Salehipour A; Bazl MSY; Rezaei N; Mansouri A; Borghei-Razavi H
J Neuroimmunol; 2023 Aug; 381():578146. PubMed ID: 37451079
[TBL] [Abstract][Full Text] [Related]
15. Sonodynamic therapy and magnetic resonance-guided focused ultrasound: new therapeutic strategy in glioblastoma.
Bonosi L; Marino S; Benigno UE; Musso S; Buscemi F; Giardina K; Gerardi R; Brunasso L; Costanzo R; Iacopino DG; Maugeri R
J Neurooncol; 2023 May; 163(1):219-238. PubMed ID: 37179515
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapeutic Drugs: DNA Damage and Repair in Glioblastoma.
Annovazzi L; Mellai M; Schiffer D
Cancers (Basel); 2017 May; 9(6):. PubMed ID: 28587121
[TBL] [Abstract][Full Text] [Related]
17. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
18. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
19. Advances in Glioblastoma Therapy: An Update on Current Approaches.
Angom RS; Nakka NMR; Bhattacharya S
Brain Sci; 2023 Oct; 13(11):. PubMed ID: 38002496
[TBL] [Abstract][Full Text] [Related]
20. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Han J; Chu J; Keung Chan W; Zhang J; Wang Y; Cohen JB; Victor A; Meisen WH; Kim SH; Grandi P; Wang QE; He X; Nakano I; Chiocca EA; Glorioso Iii JC; Kaur B; Caligiuri MA; Yu J
Sci Rep; 2015 Jul; 5():11483. PubMed ID: 26155832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]